Reply To: Nivolumab dosing and Medicare

[Krista Rubin]

Wow- Lisa- thanks for posting this Very important information.
Our group has not yet decided what we are going to do as there are a couple of issues we are planning to discuss as a group. The information you provide Lisa, will need to factor into this as well.

The issues our team felt needed to discussed include:
–> our group has some concern about going 4 weeks between visits. While the schedule is more convenient for patients, it minimizes the chances of “early intervention” which we know is so very important when screening for toxicity.

–> anecdotal experience suggests there may be a higher incidence of infusion reaction at this dose. I have inquired with BMS regarding formal data in his regard. So- PLEASE NOTE- this is ANECDOTAL. But, if indeed true, if is important to consider

Thanks again Lisa- for sharing this info!!